Chemoenzymatic synthesis of unmodified heparin oligosaccharides: cleavage of p-nitrophenyl glucuronide by alkaline and Smith degradation by Zhang, Xing et al.
Chemoenzymatic synthesis of unmodified heparin 
oligosaccharides: Cleavage of p-nitrophenyl glucuronide by 
alkaline and Smith degradation
Xing Zhanga, Yongmei Xub, Po-Hung Hsiehb, Jian Liub, Lei Lina, Eric Schmidtc, and Robert 
J. Linhardta
aDepartments of Chemistry and Chemical Biology, Chemical and Biochemical Engineering, 
Biology, Biomedical Engineering, Rensselaer Polytechnic Institute, 110 8th Avenue, Troy, New 
York 12180
bDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, 
University of North Carolina, Chapel Hill, North Carolina 27599
cUniversity of Colorado Denver, Dept. of Medicine, Research Complex 2, 12700 E. 19th Avenue, 
Aurora CO 80045 and Denver Health Medical Center, 660 Bannock Street, Denver CO 80204
Abstract
A heparin oligosaccharide having a completely natural structure was successfully synthesized 
through a chemoenzymatic approach using an unnatural glycosyl acceptor, p-nitrophenyl 
glucuronide (GlcA-pNP). The use of an inexpensive and commercially available GlcA-pNP 
acceptor facilitates oligosaccharide recovery and purification on C-18 resin during 
chemoenzymatic synthesis. Oligosaccharide chain extension and modification afforded a 
heptasaccharide with gluconic acid residues at its reducing and non-reducing ends. Treatment with 
periodate oxidation followed by Smith degradation or alkaline elimination resulted in the selective 
cleavage of vicinal diol-containing glucronic acid residues affording highly sulfated heparin 
pentasaccharide having a completely natural structure. This methodology should facilitate the 
chemoenzymatic synthesis of a family of highly sulfated heparin oligosaccharides with 
unmodified structures for biological evaluation.
Heparin is the most highly sulfated member of the heparan sulfate (HS) family of linear, 
highly anionic polysaccharides1. HS consists of repeating, 1→4-linked disaccharide units of 
alternating uronic acid residue, either β-D-glucuronic acid (GlcA) or α-L-iduronic acid 
(IdoA) and α-D-glucosamine (GlcN) residue2–4. Both saccharide units in the HS 
disaccharide repeating units can be substituted with N-sulfo (S) or N-acetyl (Ac) groups and 
O-sulfo (S) groups (at the 2-O-position of the uronic acid residues and the 3-O- and 6-O-
positions of the GlcN residue). Heparin is a unique form of HS, found within specialized 
granulated cells4, which has long highly sulfated domains5 consisting primarily of the 
trisulfated disaccharide repeating unit →4) IdoA2S (1→4) GlcNS6S (1→4.
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Highly sulfated heparin chains display a number of prominent biological activities including 
growth factor6–8 and chemokine9 signaling and anticoagulant activity10. The 
pentasaccharide sequence containing a →4) IdoA2S (1→4) GlcNS6S (1→ at its reducing 
end with a central GlcNS3S6S residue, having the structure, 
→GlcNS6S→GlcA→GlcNS3S6S→IdoA2S→GlcNS6S→ (Fig. 1), is responsible for its 
specific binding to the serine protease inhibitor (Serpin) antithrombin III (AT). This AT 
pentasaccharide binding site has been chemically synthesized as the O-methylglycoside and 
is used clinically as an antithrombotic agent known as the ultra-low molecular weight 
heparin (ULMWH) fondaparinux (Arixtra®)11. Fondaparinux is a specific anti-factor Xa 
(FXa) agent and acts by binding to an allosteric site on AT making it a potent FXa 
inhibitor12, 13. Unfractionated heparins (UFHs), low molecular weight heparins (LMWHs) 
can contain a repeating trisulfated disaccharide sequence ([→4) IdoA2S (1→4) GlcNS6S 
(1→]6) flanking their AT pentasaccharide binding sites. This trisulfated disaccharide rich 
domain corresponds to heparins thrombin (FIIa) binding site and facilitates the assembly of 
the ternary heparin-AT-FIIa complex required for heparin’s global anticoagulant activity14.
UFH and LMWH are polypharmacological agents, complex mixtures of molecules prepared 
from animal tissues15. The supply chain of pharmaceutical heparin has been poorly 
regulated and this presented safety concerns. A worldwide distribution of contaminated 
heparin in 2007, caused by its adulteration with a semi-synthetic oversulfated chondroitin 
sulfate contaminant, adversely affected the purity and safety of animal-sourced UFH and 
LMWH, and was associated with over 200 deaths in the US16, 17. Another potential threat is 
that other bioactive entities, such as viruses or prions that might remain associated with the 
HS chains in animal extracts. Thus, the cost-effective preparation of structurally defined 
heparin oligosaccharides (ULMWH) from non-animal sources is highly desirable.
There are two ways to prepare homogeneous heparin oligosaccharides, one uses a purely 
synthetic chemical method, based on repetitive steps of protection, activation, coupling and 
de-protection, and is very challenging for molecules larger than the pentasaccharide 
Arixtra®11. Chemoenzymatic synthesis, relies on combined chemical and enzymatic 
methods, mimicking the biosynthetic pathway of heparin, and represents a promising 
strategy to address many of these synthetic challenges. Our previous studies18, 19 have 
demonstrated that chemoenzymatic synthesis is capable of generating a series of heparin 
oligosaccharides in good overall yield and possessed excellent anticoagulant activity. One 
limitation of our current chemoenzymatic synthetic approach is that we begin with an 
unnautural inexpensive commercially available acceptor, p-nitrophenyl glucuronide (GlcA-
pNP)18, 19, that is ultraviolet detectable, hydrophobic, easily binding to reversed phase 
chromatography resins, enabling the detection recovery, and purification of the resulting 
oligosaccharides using a C-18 resin. However, the resulting target molecules contain an 
unnatural structural feature. We have previously investigated the removal of pNP from 
chemoenzymatically synthesized HS oligosaccharides using ceric ammonium nitrate 20.
In the current study we faced the challenge of removing GlcA-pNP from 
chemoenzymatically synthesized highly sulfated oligosaccharide with domains consisting of 
repeating trisulfated disaccharide units. These heparin oligosaccharides represent potential 
precursors in the chemoenzymatic synthesis of Arixtra® and also display interesting 
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biological activities18,21. We report the selective removal of GlcA-pNP moiety from a more 
structurally complex heparin-like oligosaccharide using both Smith degradation and alkaline 
elimination22–24. This approach has been previously used for micro scale analysis of 
polysaccharides relying on mass spectrometry (MS) and leaves unnatural moieties at the 
reducing end of the resulting degradation products25–28. We have modified this method to 
prepare a natural heparin pentasaccharide rich in trisulfated disaccharide units.
Based on our previous effort to synthetic homogeneous low-molecular-weight heparins18, 
the chemoenzymatic synthesis of heparin-like oligosaccharide containing IdoA2S-GlcNS6S 
(where S is sulfate) repeating unit was initiated from the commercially available p-
nitrophenyl glucuronide (GlcA-pNP, 1) (Scheme 1). The monosaccharide acceptor 1 was 
repetitively elongated with PmHS2 (heparosan synthase 2 from Pasteurella multocida), 
UDP-N-trifluoroacetyl glucosamine (GlcNTFA) donor and UDP-glucuronic acid (GlcA), to 
form heptasaccharide 2. Selective removal of TFA group on nitrogen atom followed by N-
sulfation, C5 epimerization /2-O-sulfation and 6-O-sulfation produced structure 3 for further 
modification. During this chemoenzymatic synthesis, the strong UV absorbance and high 
C-18 binding affinity of the p-NP group facilitate the detection and purification of the 
intermediates. The sulfated oligosaccharides were purified by Q-Sepharose. A total of 20 mg 
of 3 was prepared.
With substrate 3 in hand, a selective oxidative-cleavage of vicinal diol was carried out with 
sodium periodate (NaIO4) in neutral sodium phosphate buffer at 37 °C29 for 3.5 h, 
furnishing the corresponding aldehyde 4, which could be used to explore the cleavage of 
GlcA-pNP group using either alkaline elimination or Smith degradation method (Scheme 2). 
The periodate oxidation was terminated by the addition of ethylene glycol followed by 
dialysis (MWCO 100–500 Da) against distilled water and lyophilization. Alkaline 
elimination method was first investigated (Scheme 2A). A solution of oligosaccharide 
aldehyde 4 was adjusted to pH 12 with 0.5 M NaOH aqueous. After standing at room 
temperature for 30 min, the solution was neutralized with 0.5 M acetic acid. The resulting 
mixture was dialyzed (MWCO 100–500 Da) against distilled water and lyophilized to obtain 
the elimination compound 5 with an unnatural enol glycoside at the reducing end. Scheme 
2B shows the Smith degradation of oligosaccharide aldehyde 4. Next, 4 was treated with 
sodium borohydride (NaBH4) in distilled water for 3 h at room temperature and then excess 
borohydride was quenched with 1 M acetic acid. After dialysis against distilled water and 
lyophilization, the oxidized-reduced oligosaccharide was dissolved in 0.5 M trifluoroacetic 
acid (TFA) solution at room temperature for 24 h. The reaction was terminated by the 
addition of 0.5 M NaOH to pH 7 and dialyzed to afford the degradation product 7. 
Gratifyingly, no glycosidic bond cleavage or de-sulfation was detected throughout this 
reaction scheme. Moreover, detection by LC-MS showed a yield of less than 5% of the 
desired target compound 8. This discovery suggested that the glycoside could be selectively 
cleaved while leaving the other glycosidic bonds within the oligosaccharide intact. Both the 
structures of 5 and 7 were clearly supported by LC-MS, 1D and 2D NMR spectrum (Fig. 2 
and Supplementary data). In the 1H spectra of alkaline elimination product 5 and Smith 
degradation product 7, the disappearance of signals at 4.52 and 5.23 ppm show that two 
GlcA residues have been successfully oxidatively cleaved (Fig. 2 I–III). The anomeric 
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signals appearing at 5.34 and 5.14 ppm confirmed the presence of GlcNS6S and IdoA2S 
residues, respectively (Fig. 2 II, III). In addition, according to H-H COSY spectrum of 
compound 5 and 7, the chemical shifts of H-2, H-4 and H-5 on IdoA residue appear at 4.26, 
4.02 and 4.76 ppm, respectively, indicating that 2-O-sulfo groups were still present on the 
IdoA residues (Fig. 2 IV, V).
Acidic hydrolysis was used to remove the unnatural glycoside in oligosaccharides 5 and 7 to 
prepare natural heparin pentasaccharide (Scheme 3). Hydrolysis of compound 5 was easier 
since enol group was more acid labile. We found that either 0.5 M TFA or 0.05 M HCl 
aqueous could successfully produce target oligosaccharide 8 in good yield with <5% starting 
material left detected by LC-MS. However, removal of the unnatural glycoside from 7 
turned out to be more challenging. Using the same conditions described above only 
recovered starting material. Finally, transformation of 7 to 8 was achieved in 0.5 M TFA 
solution at 45°C for 4 h. These reaction conditions need to be strictly controlled, as higher 
temperatures or longer reaction times result in significant decomposition. The NMR spectra 
and LC-MS of the target compound 8 clearly supports the success of this acid hydrolysis 
step (Figure 3). The anomeric signals at 5.34 and 5.14 ppm confirmed the presence of 
GlcNS6S and IdoA2S residues, respectively (Fig. 3 I). The selected anomeric and IdoA 
carbon region (64–104 ppm) in 2D 1H-13C HSQC spectrum also confirm the structure (Fig. 
3 II). The structure was also characterized by LC-MS with m/z 496.6377 in negative mode 
(Fig. 3 III).
We next expanded the oligosaccharide substrates subjected to our alkaline degradation 
method to investigate the reaction scope (Table 1). These synthetic oligosaccharides 
contained both GlcA and IdoA residues and possessed different chain lengths, sulfation 
levels, and flanking residues. The first step, periodate oxidation forming the intermediate 
aldehyde, is critical to the entire degradation process. Although it was reported that the 
neighbouring environment might influence the reactivity of uronic acid residues27, no 
selectivity in periodate cleavage was observed for unsulfured GlcA or IdoA residues within 
the oligosaccharides tested. Oligosaccharides having different residues flanking GlcA 
(entries 1–3) were fully cleaved to monosaccharides at 37 °C and pH 7.0. Oligosaccharides 
containing both unsulfated GlcA and IdoA (entries 4–5) were also fully cleaved to 
monosaccharide products, thus, no selectivity between GlcA and IdoA was observed. 
Oligosaccharides containing GlcA residues and of different chain lengths and sulfation 
levels (entries 6–8) afforded complete cleavgae of GlcA residues and afforded 
oligosaccharides of chain lengths expected based on the spacing of these GlcA residues.
In conclusion, an unmodified heparin heptaasaccharide was successfully prepared through a 
chemoenzymatic synthesis using p-nitrophenyl glucuronide (GlcA-pNP) as a glycosylation 
acceptor, which greatly facilitates the synthesis. The selective removal of GlcA-pNP moiety 
from the reducing end of the molecule and GlcA from its non reducing end, using both 
Smith degradation and alkaline elimination, afforded the target pentasaccharide saccharide. 
To our knowledge, this is the first time to these two degradation methods has been applied to 
the preparative synthesis of an oligosaccharide. Most importantly, no de-sulfation was 
detected during the synthesis. Additional oligosaccharide substrates were investigated and 
demonstrated that this degradation method was specific for saccharide residues with vicinal 
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diols, i.e., GlcA or IdoA or residues at the non-reducing end, could be applied to diverse 
oligosaccharides containing different chain lengths, sulfation levels, and flanking residues. 
This strategy should be useful in the construction of more structurally complex heparin 
oligosaccharides. Since these targets are all natural and with a GlcNS6S residue at their 
reducing end, they could be used as precursors in the chemoenzymatic synthesis of Arixtra® 
or other oligosaccharides with therapeutic anticoagulant and antithrombotic activities.
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Figure 1. 
The antithrombin III-binding pentasaccharide found in heparin.
Zhang et al. Page 7
Org Biomol Chem. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
NMR characterization of degradation oligosaccharides (R = pNP). Panel I, II, III show the 
1D 1H NMR spectra of compound 3, 5 and 7, respectively. Peaks corresponding to the 
anomeric protons of these compounds can be clearly identified. Panel IV, V show the 
selected H-H correlation in 2D H-H COSY spectrum of compound 5 and 7, respectively. 
Three sets of peaks between 3.4–3.7 ppm in 1H NMR spectrum were from glycerol that 
came from the dialysis membrane.
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Figure 3. 
NMR and HRMS of natural heparin oligosaccharide 8. Panel I shows the 1D 1H NMR 
spectrum. Panel II shows the selected anomeric and IdoA2S carbon region (64–104 ppm) in 
2D 1H-13C HSQC spectrum. Panel III shows the HRMS (negative mode) of compound 8.
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Scheme 1. 
Construction of heparin-like heptasaccharide (3)
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Scheme 2. 
GlcA-pNP cleavage via alkaline elimination (A) and Smith degradation (B).
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Scheme 3. 
Acidic hydrolysis of glycoside on degradation oligosaccharides.
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Table 1
Alkaline Smith degradation of different synthetic oligosaccharides.
Entry Substrates Productsa
1 GlcNAc-GlcA-(GlcNAc-GlcA)5-GlcNAc-GlcA-pNP Monosaccharide-R
2 GlcNS-GlcA-(GlcNS-GlcA)5-GlcNS-GlcA-pNP Monosaccharide-R
3 GlcNS6S-GlcA-(GlcNS6S-GlcA)5-GlcNS6S-GlcA-pNP Monosaccharide-R
4 GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-pNP Monosaccharide-R
5 GlcNS6S-GlcA-GlcNS6S3S-IdoA-GlcNS6S-GlcA-pNP Monosaccharide-R
6 GlcNS6S-GlcA-(GlcNS6S-IdoA2S)5-GlcNS6S-GlcA-pNP Undecassaccharide-Rb
7 GlcNS6S-GlcA-(GlcNS6S-IdoA2S)7-GlcNS6S-GlcA-pNP Pentadecasaccharide-Rb
8 GlcNS-GlcA-(GlcNS-IdoA2S)7-GlcNS-GlcA-pNP Pentadecassaccharide-Rb
a
R=C4H3O3 (see 5 in Scheme 2 for structure of aglycone).
bConfirmed by LC-MS (see Supplemental Information).
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